Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00099567|
Recruitment Status : Completed
First Posted : December 17, 2004
Last Update Posted : November 1, 2005
|Condition or disease|
The metabolic syndrome is a clustering of several commonly occurring disorders that include abdominal obesity, high triglycerides, low HDL cholesterol, high blood pressure, and insulin resistance. This study was conducted to determine if, as hypothesized, the presence of the metabolic syndrome is associated with more cognitive decline and greater risk of developing cognitive impairment, and whether this risk is affected by the level of inflammatory markers in the blood.
This 5-year prospective observational study was conducted from 1997 to 2002 at community clinics in two locations. A total of 2632 black and white participants, aged 70 to 79 years, were recruited from the 3075 participants in the Health, Aging and Body Composition (ABC) study conducted during the same period. Participants were screened for presence of metabolic syndrome, cognitive status, inflammatory markers, and a clinic examination was administered, when the study began and at the year 3 and 5 follow-up visits.
|Study Type :||Observational|
|Estimated Enrollment :||2632 participants|
|Observational Model:||Natural History|
|Official Title:||Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline|
|Study Start Date :||January 1997|
|Estimated Study Completion Date :||December 2002|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00099567
|United States, Pennsylvania|
|Pittsburgh, Pennsylvania, United States|
|United States, Tennessee|
|Memphis, Tennessee, United States|
|Principal Investigator:||Kristine Yaffe, MD||University of California, San Francisco|